c-Met targeted therapy of cholangiocarcinoma

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 19

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

332

HTML

2860

Figures (1-2)

163

Tables (1-1)

128

Sum=3483

May 21, 2008 (publication date) through May 7, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. May 21, 2008; 14(19): 2990-2994
Published online May 21, 2008. doi: 10.3748/wjg.14.2990

Table 1 Target sites of c-Met therapies

Target	Example	Current phase
HGF/c-met monoclonal antibody	AMG102[33]	Phase II
Soluble c-met receptor	Decoy met[35]	Phase I
Tyrosine kinase inhibition	ARQ 197[42]	Phase II
	XL880[36 37]	Phase II
	PHA665752[38]	Animal testing

Citation: Socoteanu MP, Mott F, Alpini G, Frankel AE. c-Met targeted therapy of cholangiocarcinoma. World J Gastroenterol 2008; 14(19): 2990-2994
URL: https://www.wjgnet.com/1007-9327/full/v14/i19/2990.htm
DOI: https://dx.doi.org/10.3748/wjg.14.2990